The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
- Homepage
- cryptocurrency
- Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
Related
Trending
Popular
© Tayedi Search engine 2025. All rights are reserved